Nevro Announces Presentation of SENZA-NSRBP Clinical Data at American Society of Interventional Pain Physicians 23rd Annual Meeting
REDWOOD CITY, California, June 22, 2021 / PRNewswire / – Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that data from the SENZA Non-Surgical Refractory Back Pain (NSRBP)) A randomized controlled trial (RCT) to be presented to the American Society of Interventional Pain Physicians (ASIPP) 23rd annual meeting to be held in person from June 24-26, 2021 at the Hilton New Orleans Riverside in New Orleans, Louisiana. Nevro will also showcase the company’s HFX™ Spinal Cord Stimulation Solutions (SCS) platform in an exhibition booth and will host an investor briefing.
The podium presentation will describe the results of the 6-month follow-up of the SENZA-NSRBP RCT. The objective of this study was to compare Nevro’s proprietary high-frequency (10 kHz) SCS plus conventional medical management (CMM) to CMM alone in 159 patients randomized to 15 study centers. The previously presented 3-month results demonstrated a higher response rate and significant pain relief for the 10 kHz SCS cohort compared to the CMM.
“This will be the first time that 6-month data from our SENZA-NSRBP clinical trial will be presented, and we look forward to Dr. Kapural sharing these significant results at the ASIPP annual meeting,” said D. Keith grossman, chairman and chief executive officer and chairman of Nevro. “The NSRBP represents an important growth engine for Nevro, and these results will provide valuable evidence to guide clinical decisions and support our initiatives to expand payor coverage as we continue to increase penetration in the non-surgical portion of our business. market. ”
The agenda for the ASIPP Annual Meeting is available at https://asipp.org/wp-content/uploads/ASIPP23rdAnnualMeetingAgenda.pdf. Details of the clinical data presentation of SENZA-NSRBP are included below:
Six-month results of a randomized clinical trial on the effectiveness of 10 kHz spinal cord stimulation for treating refractory non-surgical back pain
Presenting Author: Leonardo Kapural, MD, PhD
Date and hour : Friday 25 June 2021 during breakout sessions – Summary of Session A of 3:30 p.m. to 5:30 p.m. Central
The company plans to publish these results over 6 months in a peer-reviewed journal. Study participants will continue to be followed for 24 months.
Nevro will host a briefing for analysts and investors on June 25, 2021
Nevro will host a briefing for analysts and investors on friday 25 june, starting at 3:30 p.m. PT / 6:30 p.m. ET. Nevro President, CEO and Chairman D. Keith Grossman will host the event, which will include a clinical data update for the company’s SENZA-PDN and SENZA-NSRBP clinical studies and a question and answer session. Nevro’s chief medical officer, David Carvi, MD, PhD, and CFO of Nevro, Rod MacLeod, will also participate in the event.
Investors interested in listening to the briefing can participate via conference call or webcast. The conference call can be accessed by dialing (833) 968-2321 in the US or +1 7785602840 internationally, using the conference ID: 2819815. The live audio webcast can be accessed by clicking on the link Investor Events at https: // nevro. com / English / us / investors / events-and-presentations / event-details / 2021 / Nevro-to-Host-Virtual-Investor-Briefing-from-ADA / default.aspx on June 25. This event is not part of the official annual meeting of ASIPP.
About the American Society of Interventional Pain Physicians
ASIPP is a professional, non-profit organization founded in 1998 that now includes more than 4,500 interventional pain physicians and other practitioners who are dedicated to ensuring safe, appropriate and equal access to essential pain management services for patients across the country with chronic and acute pain. . There are approximately 8,500 trained and qualified physicians practicing interventional pain management in United States. The ASIPP is made up of 50 affiliated state corporations and the Puerto Rico Society of Interventional Pain Physicians. For more information, please visit the ASIPP website at asipp.org.
Publication of information on the Internet
Nevro regularly posts information that may be important to investors in the “Investor Relations” section of its website at www.nevro.com. The company encourages investors and potential investors to regularly check the Nevro website for important information about Nevro.
Based at Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life for patients with chronic debilitating pain. Nevro has developed and marketed the Senza Spinal Cord Stimulation System (SCS), an evidence-based, non-pharmacological neuromodulation platform for the treatment of chronic pain. Nevro’s proprietary 10 kHz therapy has been shown to reduce or eliminate opioids in ≥ 65% of patients in six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza®Omnia™System are the only SCS systems that offer Nevro’s proprietary 10 kHz therapy.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the The HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.
To learn more about Nevro, connect with us atLinkedIn,Twitter,FacebookandInstagram.
In addition to historical information, this press release contains forward-looking statements reflecting the Company’s current beliefs and expectations of management in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the company’s belief that NSRBP is a growth engine and that SENZA-NSRBP’s results will provide valuable evidence to guide clinical decisions and support the Company’s initiatives to expand payor coverage as it continues to grow. increase its penetration in the non-surgical portion of the SCS market. These forward-looking statements are based on information currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully market our products; our ability to manufacture our products to meet demand; the level and availability of reimbursement by a third party payer for our products; our ability to effectively manage our anticipated growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of others; competition in our industry; additional capital and availability of credit; our ability to attract and retain qualified personnel; and product liability claims. These factors, as well as those described in more detail in our Quarterly Report on Form 10-Q filed on May 5, 2021, as well as any reports we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or suggested by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or any commitment to update or revise these forward-looking statements.
Investors and media:
Julie dewey, SHOUT
Vice-President, Investor Relations and Corporate Communications
650-433-3247 | [email protected]
SOURCE Nevro Corp.